PHASE 2 STUDY OF A LIVE ATTENUATED MEASLES VIRUS-VECTORED CHIKUNGUNYA VACCINE IN PREVIOUSLY EXPOSED VERSUS UNEXPOSED ADULTS AGE 51 TO 65

$2,528,344FY2018Defense Health AgencyDOD

The Geneva Foundation

Investigators